CL2013000580A1 - Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit. - Google Patents

Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit.

Info

Publication number
CL2013000580A1
CL2013000580A1 CL2013000580A CL2013000580A CL2013000580A1 CL 2013000580 A1 CL2013000580 A1 CL 2013000580A1 CL 2013000580 A CL2013000580 A CL 2013000580A CL 2013000580 A CL2013000580 A CL 2013000580A CL 2013000580 A1 CL2013000580 A1 CL 2013000580A1
Authority
CL
Chile
Prior art keywords
stem cells
composition
rary
stimulation
administering
Prior art date
Application number
CL2013000580A
Other languages
English (en)
Inventor
Masahiro Iwamoto
Maurizio Pacifici
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45773490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000580(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of CL2013000580A1 publication Critical patent/CL2013000580A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Método de regeneración o reparación muscular que comprende administrar un antagonista del receptor de ácido retinoico gama (RARY); método para la inducción o estimulación de diferenciación miogénica de células madre; composición que comprende células madre mesenquimales; composición farmacéutica; kit.
CL2013000580A 2010-09-01 2013-02-28 Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit. CL2013000580A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37899610P 2010-09-01 2010-09-01

Publications (1)

Publication Number Publication Date
CL2013000580A1 true CL2013000580A1 (es) 2013-07-12

Family

ID=45773490

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000580A CL2013000580A1 (es) 2010-09-01 2013-02-28 Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit.

Country Status (20)

Country Link
US (5) US9789074B2 (es)
EP (3) EP2613776B1 (es)
JP (1) JP5986570B2 (es)
CN (2) CN103200937B (es)
AU (1) AU2011296080B2 (es)
BR (1) BR112013004685B1 (es)
CA (1) CA2809374C (es)
CL (1) CL2013000580A1 (es)
CO (1) CO6680694A2 (es)
DK (2) DK2613776T3 (es)
EA (1) EA026251B1 (es)
ES (2) ES2912593T3 (es)
HU (2) HUE059024T2 (es)
IL (1) IL224973B (es)
MX (2) MX361414B (es)
NZ (1) NZ607547A (es)
PL (2) PL3721880T3 (es)
PT (1) PT2613776T (es)
WO (1) WO2012030919A2 (es)
ZA (1) ZA201301536B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2613776B1 (en) 2010-09-01 2020-07-29 Thomas Jefferson University Composition and method for muscle repair and regeneration
US11963964B2 (en) 2011-06-16 2024-04-23 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
US9782417B2 (en) 2011-06-16 2017-10-10 Presidents And Fellows Of Harvard College Methods of increasing satellite cell proliferation with kinase inhibitors
US11026952B2 (en) 2011-06-16 2021-06-08 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
EP2918290B1 (en) 2012-11-08 2020-09-02 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
JP6509126B2 (ja) * 2013-01-09 2019-05-08 インターナショナル ステム セル コーポレイション 皮膚の再生を促進する小分子
EP3446690A1 (en) * 2013-05-22 2019-02-27 Yamaguchi University Inhibitor for retinochoroidal disorders
WO2015188015A1 (en) 2014-06-04 2015-12-10 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
US9784665B1 (en) * 2014-12-29 2017-10-10 Flagship Biosciences, Inc. Methods for quantitative assessment of muscle fibers in muscular dystrophy
RU2724525C2 (ru) * 2015-05-06 2020-06-23 Юниверсити Оф Саутерн Калифорния Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
JP2019507186A (ja) * 2016-02-01 2019-03-14 プレジデント アンド フェローズ オブ ハーバード カレッジ マウス衛星細胞の増殖のための小分子
EP4249490A3 (en) 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
KR20190100187A (ko) 2016-11-16 2019-08-28 클레멘티아 파마슈티컬즈, 인크. 다중 골연골종(mo)을 치료하는 방법
CA3019069A1 (en) * 2018-04-02 2019-10-02 Hubit Genomix, Inc. Prophylactic and/or therapeutic drug for diabetic nephropathy
WO2023241717A1 (zh) * 2022-06-16 2023-12-21 中国科学院动物研究所 促进哺乳动物器官再生修复的物质及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JPS6253981A (ja) 1985-09-02 1987-03-09 Koichi Shiyudo 新規安息香酸誘導体
KR0139216B1 (ko) 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
CA2129773C (en) 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5408002A (en) 1993-09-09 1995-04-18 Minnesota Mining And Manufacturing Company Azlactone-functional polymer blends, articles produced therefrom and methods for preparing both
US5498795A (en) 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5807900A (en) 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
CA2288690A1 (en) * 1997-05-13 1998-11-19 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration using human mesenchymal stem cells
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
DK1082410T3 (da) 1998-05-29 2007-11-26 Osiris Therapeutics Inc Humane CD45 - og/eller fibroblast mesenchymale stamceller
US6331570B1 (en) 1998-09-24 2001-12-18 Bristol-Myers Squibb Company Active enantiomer of RARγ-specific agonist
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
CA2402413A1 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
ATE328067T1 (de) 2000-04-28 2006-06-15 Childrens Medical Center Isolierung von mesenchymalen stammzellen und deren verwendung
ATE413375T1 (de) 2000-10-02 2008-11-15 Hoffmann La Roche Retinoide zur behandlung von emphysem
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1430024A1 (en) 2001-09-18 2004-06-23 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
CN1301968C (zh) 2001-09-18 2007-02-28 霍夫曼-拉罗奇有限公司 取代的脲的类维生素a激动剂ⅱ
AUPR892501A0 (en) * 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US7592174B2 (en) 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
RU2004138292A (ru) * 2002-06-04 2005-06-10 Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) Новые лиганды в качестве ингибиторов рецепторов rar, способы их получения и применение в медицине и косметике для человека
KR20050054907A (ko) * 2002-07-03 2005-06-10 폰다지오네 센트로 산 라파엘 델 몬테 테이보 조직 손상의 치료 및/또는 조직 회복의 촉진에서ｈｍｇｂ1 단백질의 용도
CA2493871A1 (en) 2002-07-16 2004-01-22 Hadi Aslan Methods of implanting mesenchymal stem cells for tissue repair and formation
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
FR2894960B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteurs rar-gamma
FR2894959B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteur rar-gamma
US20090117203A1 (en) * 2006-03-23 2009-05-07 Tmrc Co., Ltd. Kit for cancer treatment and pharmaceutical composition for cancer treatment
DK2026778T3 (en) 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US8969350B2 (en) 2008-12-18 2015-03-03 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
EP2393915A4 (en) * 2009-02-05 2012-12-26 Regenertech Pty Ltd PROCESS FOR THE PREPARATION OF PRECURSOR CELLS FROM DIFFERENTIATED CELLS
WO2011011513A1 (en) 2009-07-21 2011-01-27 University Of Washington Through Its Center For Commercialization Inhibition of pathological bone formation
UA50725U (ru) * 2009-12-01 2010-06-25 Институт Нейрохирургии Им. Акад. А.П. Ромоданова Амн Украины Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека
EP2613776B1 (en) 2010-09-01 2020-07-29 Thomas Jefferson University Composition and method for muscle repair and regeneration
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013006372A1 (en) 2011-07-01 2013-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating pathologic heterotopic ossification
KR102092988B1 (ko) 2012-09-28 2020-03-25 벤더르빌트 유니버시티 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들
JP2016510745A (ja) 2013-03-04 2016-04-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
EP3446690A1 (en) 2013-05-22 2019-02-27 Yamaguchi University Inhibitor for retinochoroidal disorders
US20170305883A1 (en) 2014-10-01 2017-10-26 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting BMP
WO2017070194A1 (en) 2015-10-19 2017-04-27 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
JP6589119B2 (ja) 2015-12-24 2019-10-16 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ 異所性骨化を治療する方法
EP4249490A3 (en) 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
JP6630255B2 (ja) 2016-09-30 2020-01-15 株式会社沖データ 画像形成装置及び通信システム

Also Published As

Publication number Publication date
EA201370051A1 (ru) 2014-03-31
EP2613776B1 (en) 2020-07-29
US20200069620A1 (en) 2020-03-05
MX361414B (es) 2018-12-05
AU2011296080B2 (en) 2014-12-04
CN103200937A (zh) 2013-07-10
CN103200937B (zh) 2020-07-03
EP3721880B1 (en) 2022-02-02
CN111773213B (zh) 2023-02-24
US20140363402A1 (en) 2014-12-11
EP3721880A1 (en) 2020-10-14
EP4066826B1 (en) 2024-03-06
WO2012030919A2 (en) 2012-03-08
CN111773213A (zh) 2020-10-16
JP5986570B2 (ja) 2016-09-06
JP2013536855A (ja) 2013-09-26
DK3721880T3 (da) 2022-05-09
IL224973B (en) 2018-06-28
MX2013002275A (es) 2013-05-22
WO2012030919A3 (en) 2012-07-05
HUE051664T2 (hu) 2021-03-29
EP4066826C0 (en) 2024-03-06
US20180000762A1 (en) 2018-01-04
CA2809374A1 (en) 2012-03-08
BR112013004685B1 (pt) 2021-09-21
PL2613776T3 (pl) 2021-01-11
EP2613776A4 (en) 2014-03-12
BR112013004685A2 (pt) 2019-04-24
MX2018015032A (es) 2021-12-08
US20140303223A1 (en) 2014-10-09
HUE059024T2 (hu) 2022-10-28
DK2613776T3 (da) 2020-10-19
ES2912593T3 (es) 2022-05-26
NZ607547A (en) 2015-06-26
US10292954B2 (en) 2019-05-21
US9789074B2 (en) 2017-10-17
AU2011296080A1 (en) 2013-03-14
US11433039B2 (en) 2022-09-06
US9314439B2 (en) 2016-04-19
US20230201146A1 (en) 2023-06-29
PL3721880T3 (pl) 2022-05-23
EP4066826A1 (en) 2022-10-05
ES2823234T3 (es) 2021-05-06
EP2613776A2 (en) 2013-07-17
CO6680694A2 (es) 2013-05-31
PT2613776T (pt) 2020-10-21
CA2809374C (en) 2021-02-23
EA026251B1 (ru) 2017-03-31
ZA201301536B (en) 2015-06-24

Similar Documents

Publication Publication Date Title
CL2013000580A1 (es) Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit.
DOP2012000105A (es) Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes
CR20150370A (es) Compuestos antivirales
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
EP2726001A4 (en) METHOD AND DEVICE FOR RESTRICTING THE JOINTLOCK ON THE HIP JOINT INCLUDING PROVISION AND USE OF A NOVEL SEAM ANCHORING SYSTEM THEREFOR
PH12014502217A1 (en) Methods for improving diaphragm function
CL2014003026A1 (es) Compuestos heterobiciclicos derivados de imidazopiridina, imidazopirazina, triazolopiridina y triazolopirazina, inhibidores de la actividad nampt; composicion farmaceutica que los comprende; y metodo para tratar trastornos inflamatorios y de reparacion de tejido, dermatosis y enfermadades autoinmunes.
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
PE20151079A1 (es) Tratamiento para artritis reumatoide
MX2012013740A (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
EA201390948A1 (ru) Лечение боли, обусловленной смещением базального слоя эндометрия
MX340816B (es) Compuestos que inhiben el glioblastoma y su uso.
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
NZ624726A (en) Methods for treating gout flares
CR20130106A (es) Nuevos moduladores de trpv3
AR089320A1 (es) Cepa de lactobacillus mucosae
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2015009606A (es) Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular.
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
BR112013005786A2 (pt) preparação de ácido 6-aminocapróico de ácido alfa-cetopimélico
UA59766U (ru) Способ медицинской реабилитации взрослых больных с посттравматическими стрессовыми расстройствами
UA76796U (ru) Способ реабилитации больных гипотиреозом вследствие тиреоидэктомии